MX2012008222A - Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas. - Google Patents

Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas.

Info

Publication number
MX2012008222A
MX2012008222A MX2012008222A MX2012008222A MX2012008222A MX 2012008222 A MX2012008222 A MX 2012008222A MX 2012008222 A MX2012008222 A MX 2012008222A MX 2012008222 A MX2012008222 A MX 2012008222A MX 2012008222 A MX2012008222 A MX 2012008222A
Authority
MX
Mexico
Prior art keywords
rtk
methods
receptor tyrosine
inhibitors
tyrosine kinases
Prior art date
Application number
MX2012008222A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Schlessinger
Irit Lax
Jae Hyun Bae
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2012008222A publication Critical patent/MX2012008222A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
MX2012008222A 2010-01-14 2011-01-13 Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas. MX2012008222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33595010P 2010-01-14 2010-01-14
PCT/US2011/021109 WO2011088196A2 (en) 2010-01-14 2011-01-13 Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2012008222A true MX2012008222A (es) 2012-08-17

Family

ID=44304965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008222A MX2012008222A (es) 2010-01-14 2011-01-13 Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas.

Country Status (14)

Country Link
US (1) US20120328599A1 (enrdf_load_stackoverflow)
EP (1) EP2523679A4 (enrdf_load_stackoverflow)
JP (1) JP2013517282A (enrdf_load_stackoverflow)
KR (1) KR20120130758A (enrdf_load_stackoverflow)
CN (1) CN102762221A (enrdf_load_stackoverflow)
AU (1) AU2011205297A1 (enrdf_load_stackoverflow)
BR (1) BR112012016992A2 (enrdf_load_stackoverflow)
CA (1) CA2786276A1 (enrdf_load_stackoverflow)
IL (1) IL220206A0 (enrdf_load_stackoverflow)
IN (1) IN2012DN05017A (enrdf_load_stackoverflow)
MX (1) MX2012008222A (enrdf_load_stackoverflow)
RU (1) RU2012134637A (enrdf_load_stackoverflow)
SG (1) SG181850A1 (enrdf_load_stackoverflow)
WO (1) WO2011088196A2 (enrdf_load_stackoverflow)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687896A1 (en) 2007-06-05 2008-12-18 Yale University Antibody directed against the d4 ig-like domain of the kit receptor
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
EP3381943B1 (en) 2012-07-25 2022-03-16 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
JP2016506914A (ja) 2013-01-16 2016-03-07 アンセルムInserm 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド
WO2014201034A2 (en) * 2013-06-10 2014-12-18 Ansun Biopharma, Inc. Treatment for polyomavirus infection
PT3708583T (pt) 2013-08-01 2022-05-13 Five Prime Therapeutics Inc Anticorpos anti-fgfr2iiib afucosilados
JO3515B1 (ar) 2013-10-18 2020-07-05 Eisai R&D Man Co Ltd مثبطات fgfr4 بيريميدين
CN106659782B (zh) 2014-05-23 2021-11-09 塞尔德克斯医疗公司 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体
WO2016168331A1 (en) 2015-04-14 2016-10-20 Eisai R&D Management Co., Ltd. Crystalline fgfr4 inhibitor compound and uses thereof
US11447553B2 (en) 2015-11-23 2022-09-20 Five Prime Therapeutics, Inc. FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EP3454898B1 (en) 2016-05-10 2021-11-10 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
CN110283803B (zh) * 2016-06-02 2021-08-03 天津科技大学 一种磷脂酶d及其制备磷脂酸、磷脂酰丝氨酸的方法
EP3481859B1 (en) 2016-07-07 2022-04-13 Pfizer Inc. Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
CN118416216A (zh) 2017-05-16 2024-08-02 戊瑞治疗有限公司 癌症治疗中抗fgfr2抗体与化学治疗剂的组合
CA3189470A1 (en) 2020-08-21 2022-02-24 Yves SABBAGH Fgfr3 antibodies and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426396B2 (en) * 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia

Also Published As

Publication number Publication date
EP2523679A2 (en) 2012-11-21
SG181850A1 (en) 2012-08-30
US20120328599A1 (en) 2012-12-27
BR112012016992A2 (pt) 2019-09-24
KR20120130758A (ko) 2012-12-03
IN2012DN05017A (enrdf_load_stackoverflow) 2015-10-02
WO2011088196A2 (en) 2011-07-21
JP2013517282A (ja) 2013-05-16
CN102762221A (zh) 2012-10-31
IL220206A0 (en) 2012-07-31
EP2523679A4 (en) 2013-07-24
RU2012134637A (ru) 2014-02-20
WO2011088196A3 (en) 2011-11-17
CA2786276A1 (en) 2011-07-21
AU2011205297A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
MX2012008222A (es) Inhibidores de cinasa de y tirosina receptora (rtk) y metodos de uso de las mismas.
PH12014500372A1 (en) Compounds and compositions as c-kit kinase inhibitors
TN2014000061A1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
HK1202377A1 (en) Modulating certain tyrosine kinases
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
EA201791133A1 (ru) Ингибиторы erk
MX368707B (es) Compuestos para usarse para inhibir c-kit cinasa fosforilada constitutivamente activa.
HK1204995A1 (en) Compounds and methods for kinase modulation, and indications therefor
MX389105B (es) Inhibidor de quinasas reordenadas durante la transfeccion (ret).
WO2011090738A3 (en) Type ii raf kinase inhibitors
HUE061909T2 (hu) Pirazolo[1,5-a]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére
MX2011009568A (es) Inhibidores de la rho cinasa.
PH12012501581A1 (en) Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
ES2608829T8 (es) Inhibidores de tirosina quinasa que contienen diarilacetileno hidrazida
EP2670244A4 (en) BICYCLIC AND TRICYCLIC PYRIMIDINYROSINE KINASE INHIBITORS WITH ANTITUBULIN EFFECT AND METHOD FOR THE TREATMENT OF A PATIENT
EP2931281A4 (en) AMINOPYRIDE-CONTAINING MILK TYROSINE KINASE HEMMER
MX344302B (es) Compuestos de quinazolina sustituidos con alquino y metodos uso.
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2014009277A (es) Antagonistas alk1 y sus usos en el tratamiento de carcinoma de celula renal.
EP2833886A4 (en) SUBSTITUTED QUINOLINES AS INHIBITORS OF BRUTON TYROSINE KINASES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal